survodutide

News

New diabetes and obesity studies making waves at EASD

As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.

News

ADA: Safety data offset efficacy for survodutide

New data with Zealand/Boehringer's survodutide reinforce its metabolic benefits, but a high discontinuation rate has raised concerns.

News

Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.

News

Boehringer, Lilly face off in MASH at EASL

Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associa

News

Boehringer will use Walgreens trials unit for obesity trial

Walgreens’ plans to disrupt the clinical trials sector have taken a step forward with a high-profile partnership with Boehringer Ingelheim.

News

Boehringer’s survodutide shows monster MASH potential

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the res

New diabetes and obesity studies making waves at EASD

ADA: Safety data offset efficacy for survodutide

Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Boehringer, Lilly face off in MASH at EASL

Boehringer will use Walgreens trials unit for obesity trial

Boehringer’s survodutide shows monster MASH potential

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

survodutide

Editor's Picks